Bristol-Myers Squibb (BMY) Tops Q4 EPS by 9c

Bristol-Myers Squibb (NYSE: BMY) reported Q4 EPS of $1.82, $0.09 better than the analyst estimate of $1.73. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.21 billion.

GUIDANCE:

Bristol-Myers Squibb sees FY2023 EPS of $7.95-$8.25, versus the consensus of $8.00. Total revenues are expected to increase by approximately 2% at reported rates and approximately 2% excluding foreign exchange.

For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Adobe Systems (ADBE) Tops Q2 EPS by 14c, Offers Guidance
• Stitch Fix (SFIX) Tops Q3 EPS by 4c, Offers Guidance